- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02265575
Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration (HARK)
Study Overview
Detailed Description
Subcutaneous (SC) infusion has been established in high-income countries as a safe and effective alternative to expedite and simplify IV access. , A study from 2003 demonstrated the efficacy of SC hydration in elderly patients, for example. Fluid absorption via the SC method was almost identical to that via the IV method. A recent retrospective study compared SC fluid infusion with IV fluid infusion in children and showed that the SC method makes possible a more timely delivery of parenteral fluid with fewer needlesticks.
Additionally, SC hydration has been shown to be even more effective with the addition of recombinant human hyaluronidase, an enzyme that breaks down hyaluronic acid that makes up the extracellular matrix. , (Note: Hyaluronidase, or Hylenex, is not an investigational drug; it is FDA-approved, regularly used in the U.S., and will be procured for this study through the pharmacy of the Massachusetts General Hospital (Boston, USA).) When hyaluronidase is injected subcutaneously, an area forms where fluids do not have a dense matrix to cross. Flow rates with hyaluronidase-assisted SC (hSC) infusion are nearly five times faster than SC fluid administration alone.8 U.S.-based studies comparing hSC rehydration with standard IV rehydration in children with mild-to-moderate dehydration have demonstrated several benefits of hSC, including time and success of line placement, ease of use, satisfaction, and cost-effectiveness.9, These studies concluded that hSC hydration is a reasonable alternative to IV hydration in resource-rich settings, especially for children with difficult IV access.
While hSC infusion has been shown to be safe, successful, and cost-effective in high-income countries like the United States, there have been no randomized control trials in low-resource settings. The benefits of hSC that have been demonstrated in high-income countries, namely the ease of use and cost-effectiveness, may be particularly advantageous in low- and middle-income countries. It may even be found to be safer in these settings than current standards of care in light of recent findings of higher mortality with IV bolus rehydration among febrile children with infection in Africa. We, therefore, propose a feasibility study to evaluate whether hSC infusion can be effective and safe among moderate-to-severely dehydrated patients in rural community hospitals in western Kenya.
Rationale
hSC infusion can improve clinical management of patients presenting with moderate-to-severe dehydration. It can serve as a definitive alternative rehydration method or as a bridge to IV access when IV access is unobtainable.
Hypotheses
Hyaluronidase-assisted subcutaneous fluid resuscitation is equally effective as standard IV therapy for initial volume resuscitation in moderate to severely dehydrated patients in rural Kenya.
Hyaluronidase-assisted subcutaneous fluid resuscitation can decrease costs, shorten time to IV placement (reduce needlesticks), less discomfort, and decrease complications compared to standard IV therapy in moderate to severely dehydrated patients in rural Kenya.
Research questions
This study seeks to help answer the following research questions: Can hSC be effectively introduced among mid-level providers in rural community hospitals in western Kenya? Can hSC serve as an effective and safe treatment or bridge to IV access among patients presenting with moderate-to-severe dehydration? What are the perceptions and attitudes of providers and patients upon the use of hSC? What is the cost effectiveness of hSC in this setting?
Objectives
To evaluate the efficacy of hyaluronidase-assisted subcutaneous resuscitation (hSC) in moderate to severely dehydrated patients in Kenya.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Luanda, Kenya
- Sagam Community Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients presenting to a participating facility with moderate-to-severe dehydration will be considered for participation. Other inclusion criteria will include:
- Patients over the age of 1 month
- Patients presenting with moderate-to-severe dehydration who failed to improve or are not candidates for oral rehydration therapy and IV access is not successful twice
- Parents or legal guardian(s) available to provide written informed consent
Exclusion Criteria:
- There will be no limitation based on race, tribe, language, or sexual orientation in the study for any patients who meet treatment criteria. There are no exclusions based on language. Exclusion criteria will include:
- Any condition precluding SC infusion or infusion-site evaluation in all possible anatomic locations, including the upper back, anterior thighs, abdomen, and other potential areas for hSC therapy
- Any reason (before study enrollment) for a hospital admission or extended stay for other than dehydration-related illness
- Known hypersensitivity to hyaluronidase or any ingredient in the study formulation of recombinant human hyaluronidase
- Any patient not eligible for IV or SC fluids as determined by the local clinician
- Any medical condition likely to interfere with the patient's ability to fully complete all protocol-specified interventions, the ability to undergo all protocol-specified assessments, or likely to prolong the patient's need for medical attention beyond that required for addressing the dehydration-related illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: hyaluronic acid
Rehydration using hyaluronidase-assisted subcutaneous infusion
|
rehydration using hyaluronidase-assisted subcutaneous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to recovery
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days
|
Time to normal fluid hydration status
|
participants will be followed for the duration of hospital stay, an expected average of 3 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: participants will be followed for the duration of hospital stay, an expected average of 3 days
|
participants will be followed for the duration of hospital stay, an expected average of 3 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Brett D. Nelson, MD,MPH,DTM&H, Massachusetts General Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014P001390
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dehydration
-
United States Army Research Institute of Environmental...CompletedDehydration Hypertonic | Isotonic Dehydration
-
University of HartfordArizona State University; Kraft Heinz CompanyRecruitingDehydration in Children | Dehydration Following Exertion (Disorder)United States
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...UnknownAged | Dehydration HypertonicItaly
-
University of DelawareNational Heart, Lung, and Blood Institute (NHLBI); National Institute of General...Completed
-
Rhode Island HospitalInternational Centre for Diarrhoeal Disease Research, Bangladesh; Fogarty International...Completed
-
Wayne State UniversityUniversity of ChicagoUnknown
-
University College, LondonUniversity of Portsmouth; University of WollongongUnknownDehydration HypertonicUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker CochinRecruitingMild to Moderate DehydrationFrance
-
Cedars-Sinai Medical CenterTerminatedDehydration, Diverting Ileostomy, LoperamideUnited States
-
University of Illinois at ChicagoAbbott NutritionCompleted
Clinical Trials on Hyaluronic Acid
-
Ayhman Al AfifNova Scotia Health AuthorityCompletedHead and Neck Neoplasms | Laryngeal Cancer | Head and Neck Squamous Cell Carcinoma | Voice Disorders
-
Herbarium Laboratorio Botanico LtdaCompletedVaginal Disease | Atrophic VaginitisBrazil
-
Taipei Medical UniversityShin Kong Wu Ho-Su Memorial HospitalUnknown
-
Bioventus LLCTerminatedKnee OsteoarthritisFrance, Monaco
-
Medical University of ViennaRecruiting
-
Tedec-Meiji Farma, S.A.CompletedOsteoarthritis of the KneeSpain
-
Federico II UniversityRecruiting
-
Hawler Medical UniversityCompleted
-
KLSMC Stem Cells, Inc.CompletedArticular Cartilage Disorder of Knee | Articular Cartilage; DegenerationUnited States, Malaysia
-
South China Research Center for Stem Cell and Regenerative...UnknownSenescence Wrinkles, Acne, Pitting Scar